119 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
19 Apr 24
Current report (foreign)
6:12am
if the benefits outweigh the risks. ADVERSE REACTIONS The most common adverse reactions (incidence ≥3% and ≥1% higher than placebo) were: nasopharyngitis, headache
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
14 Dec 23
Current report (foreign)
6:01am
contributes to the corporate value of the Company Group by considering the Company’s mid-to-long term business strategy, and comparing the benefits … Management Committee, changing the portfolio strategy as necessary. The committee takes into consideration the maximizing of benefits
6-K
TAK
Takeda Pharmaceutical Co
28 Sep 23
Current report (foreign)
6:17am
if the benefits outweigh the risks.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥3% and ≥1% higher than placebo) were
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
12 Jul 23
Current report (foreign)
6:07am
contributes to the corporate value of the Company Group by considering the Company’s mid-to-long term business strategy, and comparing the benefits … , changing the portfolio strategy as necessary. The committee takes into consideration the maximizing of benefits to the participants and beneficiaries
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
6 Jul 23
Current report (foreign)
6:18am
: to serve patients with integrity in a way that also benefits society. By doing so, Takeda has expanded its business to become the global values-based, R&D … increase awareness of the benefits of vaccination and investing in digital education tools for consumers such as KnowDengue.com. T H E I N T E R N AT I O N
6-K
EX-99.1
jaqis9relmrow
23 Jun 23
Current report (foreign)
6:13am
6-K
EX-99.1
l617rhquobxzai dqbg7
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
f25ouqz 8b4bugvvypg
30 May 23
Current report (foreign)
6:14am
6-K
EX-99.1
bzhgx9gohjw98ba6 0qc
30 May 23
Current report (foreign)
6:11am
6-K
kgxr2el803b7udf4p
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
wohc03f0yw0sngc
30 Nov 22
Current report (foreign)
6:28am
6-K
pfx7f5rfz91f3dx57y
4 Nov 22
Current report (foreign)
6:01am
6-K
g901ccu4685nzb8jd
27 Oct 22
Current report (foreign)
6:01am
6-K
8ps1ry 6i0
4 Aug 22
Current report (foreign)
6:07am
6-K
jrp bpnfmedum
28 Jul 22
Current report (foreign)
6:09am
6-K
r8cnjo
11 Jul 22
Current report (foreign)
6:05am